Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) CFO Kamran Alam sold 7,476 shares of the firm's stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $3.87, for a total value of $28,932.12. Following the sale, the chief financial officer now directly owns 290,645 shares of the company's stock, valued at $1,124,796.15. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Kamran Alam also recently made the following trade(s):
Get Taysha Gene Therapies alerts:- On Monday, August 22nd, Kamran Alam sold 9,717 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $3.50, for a total value of $34,009.50.
Taysha Gene Therapies Stock Performance
Shares of TSHA traded down $0.31 during mid-day trading on Monday, reaching $3.43. 69,277 shares of the company's stock were exchanged, compared to its average volume of 240,529. The business's fifty day simple moving average is $4.00 and its 200-day simple moving average is $4.77. Taysha Gene Therapies, Inc. has a 52-week low of $2.33 and a 52-week high of $21.90. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.79 and a quick ratio of 1.79. The stock has a market capitalization of $140.95 million, a PE ratio of -0.71 and a beta of 0.99.
Analyst Ratings Changes
TSHA has been the subject of several recent research reports. Needham & Company LLC cut their price target on Taysha Gene Therapies to $20.00 and set a "buy" rating for the company in a research note on Tuesday, May 17th. Guggenheim dropped their price target on shares of Taysha Gene Therapies to $22.00 and set a "na" rating on the stock in a research report on Tuesday, May 17th. Chardan Capital decreased their price target on shares of Taysha Gene Therapies from $34.00 to $32.00 and set a "buy" rating for the company in a research note on Friday, August 12th. Wedbush reduced their price target on shares of Taysha Gene Therapies from $9.00 to $5.00 and set an "outperform" rating for the company in a research report on Friday, August 12th. Finally, The Goldman Sachs Group dropped their price objective on shares of Taysha Gene Therapies from $27.00 to $16.00 and set a "buy" rating for the company in a report on Tuesday, May 24th. Eleven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $26.00.Institutional Trading of Taysha Gene Therapies
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp raised its position in shares of Taysha Gene Therapies by 1.4% during the 4th quarter. Northern Trust Corp now owns 214,970 shares of the company's stock valued at $2,504,000 after acquiring an additional 3,042 shares in the last quarter. Virtus ETF Advisers LLC lifted its stake in Taysha Gene Therapies by 39.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 11,519 shares of the company's stock worth $134,000 after acquiring an additional 3,251 shares in the last quarter. Swiss National Bank increased its position in Taysha Gene Therapies by 9.3% in the 1st quarter. Swiss National Bank now owns 41,000 shares of the company's stock worth $267,000 after purchasing an additional 3,500 shares during the last quarter. Occudo Quantitative Strategies LP grew its holdings in Taysha Gene Therapies by 17.9% in the 2nd quarter. Occudo Quantitative Strategies LP now owns 31,030 shares of the company's stock valued at $115,000 after buying an additional 4,702 shares during the last quarter. Finally, Quantum Private Wealth LLC lifted its position in shares of Taysha Gene Therapies by 3.8% in the 2nd quarter. Quantum Private Wealth LLC now owns 157,774 shares of the company's stock worth $586,000 after acquiring an additional 5,800 shares during the period. Hedge funds and other institutional investors own 46.05% of the company's stock.
About Taysha Gene Therapies
(Get Rating)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
Further Reading
- Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
- Oil Services: Who Will Lead The Rebound?
- Analog Devices Reveals Semiconductor Demand Problems
- Three Ways To Find Hot Stocks In A Tepid Market
- Here are the Multiple Stages of a Bear Market
- 3 August Earnings Reports With 'Wow' Potential
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.